Money
Otvos says LabCorp buyout ended plan to place NMR machines in labs
Peter Attia Drive
402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample
What was said
"LabCorp came along and said, We'd like to buy you because we can make more money if we don't have to pay whatever number of dollars to Lipo Science every time we do this test. So it was a purely financial decision."
Otvos says Liposcience’s goal was to become an IVD supplier, placing “Vanta” NMR analysers in clinical laboratories so NMR assays could be run widely. He claims LabCorp’s 2014 acquisition shifted the strategy to keeping NMR capability proprietary, ending broader deployment and, he says, curtailing awareness-building for new assays.
Verification status
Attributed speaker claim
Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.
Source and context
Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.
- Programme
- Peter Attia Drive
- Episode
- 402 ‒ NMR blood analysis: how mortality risk and more can be assessed from a single blood sample
- Clip time
- 1:10:35
- Original source
- Watch the source segment →
From this episode
Peter Attia Drive